Our study demonstrated a sex-dimorphic role of myeloid-FATP4 on steatotic versus inflammatory NASH, and provided insights into strategic considerations for NASH treatment in sex-specific personalized therapies. The gene discussed is SLC27A4; the disease is metabolic dysfunction-associated steatohepatitis.